Poster Session at ECC 2013 – Biology of the tumour key to treatment
Discussion of the abstract by Dr Zoran Gatalica, Adjunct Professor of Pathology at Creighton University School of Medicine .
Discussion of the abstract by Dr Zoran Gatalica, Adjunct Professor of Pathology at Creighton University School of Medicine .
Oral discussion of abstract by Professor Naredi, Sahlgrenska University Hospital, Gothenburg, Sweden. Researchers believe they have discovered how aspirin improves survival in patients diagnosed with colon cancer.
by Peter Mas Mollinedo – Improvements in diagnostics and medical treatments mean the number of patients living with cancer is increasing around the world. The World Health Organization… read more.
by Peter Mas Mollinedo reporting on the presentation by Dominique Elias, Gustave-Roussy Institute, Paris, France. – Aggressive complete cytoreductive surgery (CCRS) in combination with hyperthermic intraperitoneal chemotherapy (HIPEC)… read more.
LM Wiltink, Leiden University Medical Center, the Netherlands; Hans-Joachim Schmoll, Martin Luther University Halle – Wittenberg, Germany. A unique 14-year follow-up study from the universities of Leiden in… read more.
by Bruce Sylvester – taken from the NEJM (New England Journal of Medicine) – Addition of nab-paclitaxel to gemcitabine for treatment of advanced pancreatic cancer has resulted in… read more.
by Esther Drain reporting on the presentation by Dr Timothy Price – A randomized, multicenter, open-label, phase 3 study of panitumumab (pmab) vs cetuximab (cmab) for previously treated… read more.
Report by Esther Drain – Cetuximab resulted in a significant improvement in survival in TP53 WT, high-risk Rectal Cancer.
Taken from the European Cancer Congress ( ECCO / ESMO / ESTRO ) from the 27th September – 1st October 2013 in Amsterdam.
First ever Europe-wide study reveals that even when undergraduate medical students take a compulsory course on pain, they still only receive on average 12 hours’ training
17th ECCO – 38th ESMO – 32nd ESTRO – European Cancer Congress, Amsterdam RAI, 27 Sept – 1 Oct 2013. Eribulin represents a novel class of antineoplastic agents… read more.
A review of the presentation by Professor David Cunningham (pictured), London, UK. The risk profile of rectal tumours varies with the position and profile of the disease. David… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.